Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.
Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
Protagenic Therapeutics, Inc. is headquartered in New York, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 31, 25 | -0.24 Increased by +25.89% | - |
| Nov 12, 24 | -0.14 Increased by +49.34% | - |
| Aug 14, 24 | -0.36 Decreased by -117.44% | - |
| May 15, 24 | -0.38 Decreased by -175.07% | - |
| Nov 14, 23 | -0.32 Decreased by -502.80% | - |
| Aug 14, 23 | -0.28 Decreased by -598.25% | - |
| May 15, 23 | -0.17 Decreased by -232.60% | - |
| Mar 31, 23 | -0.14 Increased by +30.19% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by N/A% | -1.55 M Increased by +7.30% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 25.14 K Increased by +N/A% | -640.78 K Increased by +54.12% | Decreased by -2.55 K% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -1.61 M Decreased by -32.82% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 3.20 K Increased by +N/A% | -1.72 M Decreased by -140.12% | Decreased by -53.88 K% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -1.68 M Decreased by -175.96% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -1.40 M Decreased by -56.12% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -1.21 M Decreased by -81.42% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Increased by +100.00% | -718.10 K Increased by +46.77% | Decreased by N/A% Decreased by N/A% |